Clever Marketing Needed To Position J&J's New Psoriasis Drug Ahead Of Cheaper Options

 
• By Lucie Ellis-Taitt

Despite being able to show superiority over market leader AbbVie's Humira (adalimumab), Johnson & Johnson will need to invest heavily in order to drive uptake for guselkumab if the drug is successfully approved next year for the treatment of psoriasis.

Balloons
J&J's New Psoriasis Drug Will Have Stiff Competition If Approved On Back Of Strong PhIII Data • Source: Shutterstock

More from Immunological

More from Therapy Areas